Overview

CRI Worldwide, Inc., a leading provider of clinical research services to the global pharmaceutical industry, announced that it has partnered with private equity investors Ampersand Ventures and SV Life Sciences in conjunction with the company’s expansion strategy.

The company has extensive experience in conducting clinical trials related to central nervous system (CNS) disorders – one of the most rapidly growing segments of pharmaceutical research.

CRI has pioneered a unique model for conducting inpatient studies within acute care facilities, thereby providing access to physician subspecialties, specialized procedures and emergency response teams that cannot be matched by stand-alone Phase I units.

Significance

“CRI has established an exceptional model for conducting early stage learning studies in patients in an acute care environment under the safest possible conditions,” stated Earle Martin, Executive Chairman, Board of Directors, CRI Worldwide.

“This capability addresses a critical and growing need among pharmaceutical sponsors, which has led to robust growth at CRI. I look forward to working closely with the CRI management team and new investors to build on the company’s successful track record,” Mr. Martin added.

The transaction with Ampersand Ventures and SV Life Sciences represents CRI’s first institutional financing.

Crosstree’s Role

Crosstree Capital Partners served as exclusive financial advisor for CRI Worldwide, Inc.